Shokrollahi Barough, Mahdieh <br/><br/>
Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.  [electronic resource] 

 -  International immunopharmacology  Sep 2018 
 - 109-113 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1878-1705 
<br/><br/><label>Standard No.: </label>10.1016/j.intimp.2018.06.032  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>A549 Cells<br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Antibodies, Neutralizing--blood<br/>Biosimilar Pharmaceuticals--administration & dosage<br/>Cell Culture Techniques<br/>Disability Evaluation<br/>Persons with Disabilities<br/>Enzyme-Linked Immunosorbent Assay<br/>Humans<br/>Interferon beta-1a--administration & dosage<br/>Multiple Sclerosis, Relapsing-Remitting--blood